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A B S T R A C T
Background
Bronchiolitis is a serious, potentially life-threatening respiratory illness commonly affecting babies. It is often caused by respiratory
syncytial virus (RSV). Antibiotics are not recommended for bronchiolitis unless there is concern about complications such as secondary
bacterial pneumonia or respiratory failure. Nevertheless, they are often used.
Objectives
To evaluate the effectiveness of antibiotics for bronchiolitis in children under two years of age compared to placebo or other interventions.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL 2014, Issue 6), which includes the Cochrane Acute
Respiratory Infection Group’s Specialised Register, and the Database of Abstracts of Reviews of Effects, MEDLINE (1966 to June
2014), EMBASE (1990 to June 2014) and Current Contents (2001 to June 2014).
Selection criteria
Randomised controlled trials (RCTs) comparing antibiotics to placebo in children under two years diagnosed with bronchiolitis, using
clinical criteria (including respiratory distress preceded by coryzal symptoms with or without fever). Primary clinical outcomes included
time to resolution of signs or symptoms (pulmonary markers included respiratory distress, wheeze, crepitations, oxygen saturation and
fever). Secondary outcomes included hospital admissions, length of hospital stay, readmissions, complications or adverse events and
radiological findings.
Data collection and analysis
Two review authors independently analysed the search results.
Main results
We included seven studies with a total of 824 participants. The results of these seven included studies were often heterogeneous, which
generally precluded meta-analysis, except for deaths, length of supplemental oxygen use and length of hospital admission.
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In this update, we included two new studies (281 participants), both comparing azithromycin with placebo. They found no significant
difference for length of hospital stay, duration of oxygen requirement and readmission. These results were similar to an older study (52
participants) that demonstrated no significant difference comparing ampicillin and placebo for length of illness.
One small study (21 participants) with higher risk of bias randomised children with proven RSV infection to clarithromycin or placebo
and found a trend towards a reduction in hospital readmission with clarithromycin.
The three studies providing adequate data for days of supplementary oxygen showed no difference between antibiotics and placebo
(pooled mean difference (MD) (days) -0.20; 95% confidence interval (CI) -0.72 to 0.33). The three studies providing adequate data
for length of hospital stay, similarly showed no difference between antibiotics (azithromycin) and placebo (pooled MD (days) -0.58;
95% CI -1.18 to 0.02).
Two studies randomised children to intravenous ampicillin, oral erythromycin and control and found no difference for most symptom
measures.
There were no deaths reported in any of the arms of the seven included studies. No other adverse effects were reported.
Authors’ conclusions
This review did not find sufficient evidence to support the use of antibiotics for bronchiolitis, although research may be justified to
identify a subgroup of patients who may benefit from antibiotics. Further research may be better focused on determining the reasons
that clinicians use antibiotics so readily for bronchiolitis, how to reduce their use and how to reduce clinician anxiety about not using
antibiotics.
P L A I N L A N G U A G E S U M M A R Y
Antibiotics for bronchiolitis in children under two years of age
Question
We reviewed the evidence on the effect of antibiotics on clinical outcomes in children with bronchiolitis.
Background
Bronchiolitis is a serious respiratory illness that affects babies. It is most commonly caused by respiratory syncytial virus (RSV) and is the
most common reason for hospitalisation in babies younger than six months. Babies usually present with runny nose, cough, shortness
of breath and signs of difficulty in breathing, which can become life-threatening. Despite its viral cause, antibiotics are often prescribed.
Prescribers may be expecting benefits from anti-inflammatory effects attributed to some antibiotics or be concerned about secondary
bacterial infection, particularly in children who are very unwell and require intensive care.We wanted to discover if antibiotics improved
or worsened clinical outcomes in children with bronchiolitis.
Study characteristics
This evidence is current to June 2014. We identified seven trials (824 participants) comparing antibiotics with placebo or no antibiotics
in children with bronchiolitis. Two of these studies also compared intravenous and oral antibiotics.
Key results
Our primary outcome was duration of symptoms/signs (duration of supplementary oxygen requirement, oxygen saturation, wheeze,
crepitations (crackles), fever). Secondary outcomes included duration of admissions/time to discharge from hospital, readmissions,
complications/adverse events (including death) and radiological (X-ray) findings.
We included seven studies with a total of 824 participants. Four studies reported on duration of supplementary oxygen requirement
and did not demonstrate a significant difference in the duration of oxygen use comparing antibiotics to placebo. We combined three
studies comparing azithromycin versus placebo and again did not demonstrate a significant difference between antibiotics and placebo
in the duration of oxygen requirement. Most of the included studies did not report on the primary outcomes of wheeze, crepitations
and fever. One study with a high risk of bias found mixed results for the effects of antibiotics on wheeze but no difference for other
symptom measures. One study found no difference in duration of fever and one study found no difference in presence of fever on day
two.
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In regards to secondary outcomes, six included studies did not find any difference between antibiotics and placebo for the outcomes
of length of illness or length of hospital stay. For length of hospital stay, we combined data from three studies comparing the use of
azithromycin versus placebo as a subtotal as part of the overall analysis of the effect of antibiotics on hospital stay. These combined
results similarly showed no difference between antibiotics (azithromycin) and placebo. One small study with a high risk of bias found
that three weeks of clarithromycin significantly reduced hospital readmission compared to placebo. However, this reduction in hospital
readmissions was not replicated in a more recent study that randomised 97 children to receive either a single large dose of azithromycin
or placebo. There were no deaths reported in any arms of any of the seven included trials and none of the studies specifically reported
on adverse effects of antibiotics. Only two studies made general comments that no adverse effects were found with antibiotic use.
Radiological findings were not reported as an outcome in any of the included studies.
Quality of the evidence
This 2014 updated review is stronger, owing to the inclusion of two new randomised controlled trials (RCTs). These two studies
combined involved a further 138 participants in the antibiotic arm and 143 participants in the placebo arm. Prior to this only three
small RCTs had examined antibiotics versus placebo, with only 72 participants in the antibiotic arms and 72 participants in the placebo
arms. Consequently, this reviewmakes a substantial contribution, especially with regards to the role of macrolides, such as azithromycin,
in bronchiolitis. No new unpublished data have been included. However, the review authors have no reason to suspect that the search
strategy has biased the review results. Raw data could not be obtained from one study conducted 40 years ago, nor from three other
trials, which is a weakness of this review. Three trial authors did provide raw data for this review.
Conclusion
This review did not find sufficient evidence to support the use of antibiotics for bronchiolitis. Research may be justified to identify a
subgroup of patients who may benefit from antibiotics.
B A C K G R O U N D
Description of the condition
Bronchiolitis is a serious, potentially life-threatening respiratory
illness that often affects young babies. It occurs most frequently
in the first year of life and is the commonest cause of hospital
admissions in infants under six months of age (Wohl 1978). The
most commonly identified pathogen is respiratory syncytial virus
(RSV).Other viruses such as humanmeta-pneumovirus (HMPV),
influenza, parainfluenza, adenovirus and rhinovirus have also been
implicated (Williams 2004). Other less common pathogens in-
clude Mycoplasma pneumoniae (M. pneumoniae), which can oc-
cur in sporadic outbreaks (Glezen 1971; Rose 1987). The diag-
nosis is most often made on clinical grounds, which usually in-
cludes tachypnoea (rapid breathing) and wheezing in children un-
der two years of age (Bordley 2004). Immunofluorescence and
culture of the nasopharyngeal aspirate may be used to determine
the causative organism and may reduce antibiotic use (Christakis
2005). A chest X-ray may show hyperinflation and patchy atelec-
tasis (where parts of the lung collapse or do not inflate properly)
(Smyth 2006). There are few effective therapies, including antivi-
ral therapies (Smyth 2006).
Description of the intervention
Antibiotics are not recommended unless there is concern about
complications such as secondary bacterial pneumonia (Fitzgerald
2004; Lozano 2002). This is based on evidence suggesting a low
risk of bacteraemia (0.2%) in children with bronchiolitis and fever
- a lower risk than for children with a fever without a recognisable
illness, where the rate ranges from 2% to 7% (Greenes 1999).
Antibiotic use comes with significant harms including common
adverse reactions (rash, abdominal pain, diarrhoea and vomiting),
cost and community bacterial resistance (Brook 1998).
Infants with severe bronchiolitis requiring mechanical ventilation
have been shown to have high rates of bacterial co-infection. Bac-
terial co-infection rates vary from 21% (Thorburn 2006) to 26%
(Kneyber 2005), measured in both from endotracheal aspirates.
Consistent with these results, Kneyber 2005 reported antibiotic
use at 95% in infants with bronchiolitis in intensive care.
Antibiotics are commonly used in hospitalised infants, even in
children who are not ventilated, at rates of 34% (Vogel 2003),
45% (Christakis 2005; Thorburn 2006), and 99% (Kabir 2003).
In one outpatient study antibiotics were used in 53% of children
with bronchiolitis (Halna 2005).
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How the intervention might work
Antibiotics may be useful in cases of illness where superinfection
with bacteria occurs, although it is unlikely that antibiotics will
be effective for a condition that only has a viral cause. However,
some antibiotics may have anti-inflammatory effects, which may
improve symptoms.
Why it is important to do this review
The use of antibiotics for uncomplicated bronchiolitis is common
yet is not justified by our understanding of bronchiolitis as a viral
illness. The discord between clinical practice and the pathophysi-
ological understanding of bronchiolitis as a viral illness will benefit
from the empirical evidence offered by this systematic review.
O B J E C T I V E S
To evaluate the effectiveness of antibiotics for bronchiolitis in chil-
dren under two years of age compared to placebo or other inter-
ventions.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Single or double-blind randomised controlled trials (RCTs) com-
paring antibiotics to placebo or control to treat bronchiolitis.
Types of participants
Children under the age of two years diagnosed with bronchioli-
tis using clinical criteria, such as respiratory distress preceded by
coryzal symptoms, with or without fever.
Types of interventions
Oral, intravenous, intramuscular or inhaled antibiotics versus
placebo.
Types of outcome measures
Primary outcomes
Duration of symptoms/signs:
1. Duration of supplementary oxygen requirement
2. Oxygen saturation
3. Wheeze
4. Crepitations
5. Fever
Secondary outcomes
1. Duration of admission/time to discharge from hospital
2. Readmissions
3. Complications/adverse events developed, including death
4. Radiological findings
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Tri-
als (CENTRAL 2014, Issue 6), which includes the Cochrane
Acute Respiratory Infection Group’s Specialised Register, and the
Database of Abstracts of Reviews of Effects, MEDLINE (1966 to
June 2014), EMBASE (1990 to June 2014) and Current Contents
(2001 to June 2014).
We used multiple strategies to identify as many trials as possible
that met the inclusion criteria, regardless of language or publica-
tion status. We used the search strategy described in Appendix 1
to search MEDLINE and CENTRAL. We combined the MED-
LINE search strategy with the Cochrane Highly Sensitive Search
Strategy for identifying randomised trials in MEDLINE: sensitiv-
ity- and precision-maximising version (2008 revision): Ovid for-
mat (Lefebvre 2011).Wemodified these terms to search EMBASE
(Appendix 2) and Current Contents (Appendix 3).
Searching other resources
We searched the trials registries WHO ICTRP and ClinicalTri-
als.gov for completed and ongoing trials (latest search date 7 July
2014). We handsearched the references of all identified studies.
One review author (GS) and an expert librarian (LE) carried out
the search. We contacted experts in the field looking for unpub-
lished studies.
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Data collection and analysis
Selection of studies
In the original publication of this review, two review authors (GS,
CDM) independently scanned abstracts from the initial search
results to identify trials that loosely met the inclusion criteria. Two
review authors (CDM, JD) independently reviewed the full-text
articles of the retrieved trials and applied the inclusion criteria.
In the 2011 update, four further studies were found to meet the
inclusion criteria and two review authors (CDM, JD) indepen-
dently assessed the methodological quality of the new included
studies that met the inclusion criteria at that time.
Similarly, in this updated review two authors (RF, GS) scanned
abstracts from the updated searches to identify trials that met the
inclusion criteria. Two review authors (CDM, GS) independently
reviewed the full-text articles of the retrieved trials and applied the
inclusion criteria.
We identified two new papers, Pinto 2012 and McCallum 2013,
for inclusion in this 2014 updated review.
Data extraction and management
In the initial publication of this review, two review authors (CDM,
JD) independently extracted data from each study to be included,
using data extraction forms which included type of intervention,
adverse events, and continuous and dichotomous outcomes. We
also noted the setting (hospital or primary care), study population
and any additional interventions or tests.
In this update two review authors (CDM, GS) independently
extracted data from the two new included papers. We contacted
the authors of both papers to obtain original data.
Assessment of risk of bias in included studies
We rated the quality of each eligible RCT according to the ’Risk
of bias’ tool available in RevMan 2014 and criteria set out in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011). We assessed methodological quality under the headings of
allocation, blinding, incomplete outcome data, selective report-
ing and other potential sources of bias. Two review authors (GS,
CDM) independently assessed the methodological quality of the
two new included trials for this review update. We resolved any
disagreements between the review authors by discussion.
Measures of treatment effect
We analysed data using RevMan 5.3 (RevMan 2014). We ex-
pressed continuous data comparisons using mean differences
(MD), where there was one study, or standardised mean difference
(SMD), where more than one study used different measurement
scales. We expressed dichotomous data using odds ratios (OR).
We pooled data into clinical outcomes where multiple trial results
for the same clinical presentation existed and heterogeneity did
not preclude pooling of results.
Unit of analysis issues
The unit of analysis for each outcome was the individual research
participant.
Dealing with missing data
Intention-to-treat (ITT) analyses were conducted in Kneyber
2008 and Kabir 2009. In the other five included studies it is not
clear if ITT analyses were carried out. Studies were checked for
missing data and attempts were made to contact study authors
regarding missing data.
Assessment of heterogeneity
We did not undertake a meta-analysis for most clinical outcomes
owing to multiple analyses with only one or two study results. We
pooled results where we found a satisfactorily low I2 statistic and
non-significant Chi2 test results. We were only able to combine
data for deaths, duration of supplementary oxygen use and length
of hospital stay. Given there were no deaths we cannot assess het-
erogeneity for that outcome.
Assessment of reporting biases
Studies were assessed to ensure that outcomes specified in the
methods sections of included studies were reported in the results
sections.
Data synthesis
We undertook meta-analysis for outcomes where there were suffi-
cient comparable data.Only three outcomes fitted this bill: deaths,
duration of supplemental oxygen use and length of hospital stay.
We were not able to combine symptom measures owing to a lack
of comparability of outcome measures or because the timing of
measurement was irreconcilably different.We undertook narrative
synthesis of the majority of results.
Subgroup analysis and investigation of heterogeneity
Where there was significant heterogeneity we did not conduct
meta-analysis. Sub group analysis to investigate heterogeneity was
considered for groups including year of publication, types of an-
tibiotics used and hospital versus community setting.
Sensitivity analysis
Not applicable.
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R E S U L T S
Description of studies
Results of the search
Initial database searching revealed the following results: 173 arti-
cles in MEDLINE, 102 articles in EMBASE, 23 articles in CEN-
TRAL and two articles inDARE.Of these 300 articles, we rejected
297 on the basis of title and abstract alone leaving three studies.
In the 2011 update, we identified an additional 259 studies, with
35 duplicates and 220 rejected on title and abstract alone with four
studies remaining. Of the seven studies identified from initial and
updated searches, we excluded two: one because it did not involve
clinical criteria for inclusion (Friis 1984), and one because it did
not involve an antibiotic (Boogaard 2007). Five studies did meet
the inclusion criteria (Field 1966; Kabir 2009; Kneyber 2008;
Mazumder 2009; Tahan 2007).
In this 2014 update, following removal of duplicated studies, the
searches resulted in the identification of a further 169 articles. We
retrieved five articles for further evaluation. Two of these reported
data from studies that met the inclusion criteria (McCallum 2013;
Pinto 2012).We excluded three articles as they related to the study
reported in McCallum 2013 and did not include any outcome
data.
Included studies
Field 1966, Tahan 2007, Kneyber 2008, Mazumder 2009, Kabir
2009, Pinto 2012 and McCallum 2013 met the inclusion cri-
teria, randomising children to antibiotics or control groups. All
study participants were children under two years of age except for
Tahan 2007, which only included children under seven months of
age. Two studies were conducted in low-income countries, both
in Bangladesh (Kabir 2009; Mazumder 2009). These two stud-
ies compared oral erythromycin with intravenous ampicillin and
control. Two studies were conducted in upper-middle income
countries. Tahan 2007 (Turkey) compared clarithromycin with
placebo, while Pinto 2012 (Brazil) compared azithromycin with
placebo. Kneyber 2008 and McCallum 2013 were conducted in
high-income countries and compared azithromycin with placebo.
Field 1966, also conducted in a high-income country, compared
oral ampicillin with placebo. All studies included participants who
were hospitalised and only one study recruited from an outpatients
department (Mazumder 2009). Only the two most recent studies
clearly identified their funding sources (McCallum 2013; Pinto
2012).
Excluded studies
Boogaard 2007 did not study antibiotics for bronchiolitis. We ex-
cluded one study because it dealt with both pneumonia and bron-
chiolitis using crepitations and radiography as criteria for patient
selection (Friis 1984). The study did perform a subgroup analysis
of the two groups (antibiotics and placebo) based on virological
diagnosis and these results are discussed.
Risk of bias in included studies
Risk of bias is summarised in Figure 1 and Figure 2.
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Figure 1. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Figure 2. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
Allocation
Sequence generation was adequately described by Kneyber 2008,
Kabir 2009 and McCallum 2013. Field 1966 probably also used
an adequate randomisation procedure. The randomisation pro-
cess for Tahan 2007 is not adequately described and it was
not adequately described in Mazumder 2009. Only two of the
seven included studies adequately described allocation conceal-
ment (Kneyber 2008; McCallum 2013).
Blinding
Five studies described adequate blinding of participants (all in-
fants), their parents and the investigators. Two did not discuss
blinding (Kabir 2009; Mazumder 2009). Two of the studies de-
scribed blinding of the outcome assessor (McCallum 2013; Pinto
2012).
Incomplete outcome data
In the Mazumder 2009 trial, 22 participants (out of 124) were
excluded because they did not attend regular follow-up (18) or
were persistently unwell. In the Kabir 2009 trial, 17 children were
referred to tertiary care where there was access to paediatric inten-
sive care and for 15 children their parents withdrew or they left
their respective hospitals. In Tahan 2007, nine participants were
excluded because they took corticosteroids. There were only 15
participants in each group and six were excluded from the placebo
group for taking corticosteroids and three from the clarithromycin
group. In Field 1966, eight patients were excluded from the study
owing to symptom severity (three from the ampicillin group and
five from the placebo group) with an extra two participants (one
from each group) lost to follow-up at the end of the trial. There
were no drop outs from the Kneyber 2008 trial. Only one patient
was lost to follow-up in the Pinto 2012 trial. There was no loss
to follow-up for the outcome of respiratory readmission in the
McCallum 2013 trial. One participant was excluded from analysis
for the outcomes of length of stay and oxygen use as they were
randomised to the placebo group but received a macrolide within
the exclusion timeframe (McCallum 2013).
Selective reporting
We found Kabir 2009 to have a high risk of reporting bias.
Other potential sources of bias
We identified no other concerns.
Effects of interventions
Duration of symptoms/signs
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Primary outcomes
1. Duration of supplementary oxygen requirement
Four studies reported on duration of supplementary oxygen re-
quirement (Kneyber 2008; McCallum 2013; Pinto 2012; Tahan
2007). Three of these studies compared azithromycin versus
placebo (Kneyber 2008; McCallum 2013; Pinto 2012), while
Tahan 2007 compared clarithromycin to placebo.
Tahan 2007 randomised infants younger than seven months ad-
mitted to a department of paediatrics in Turkey to clarithromycin
for three weeks (15) or placebo (15) if they were found to be pos-
itive for a respiratory syncytial virus (RSV) immunofluorescent
test. Nine participants were excluded owing to corticosteroid use,
leaving 12 in the clarithromycin group and nine in the placebo
group. Duration of oxygen use in the clarithromycin group was
31 hours (interquartile range: 28 to 42) and for placebo 72 hours
(52 to 80).
Kneyber 2008 randomised infants younger than 24 months with
clinically suspected viral bronchiolitis who were admitted to hos-
pital in theNetherlands to azithromycin (32 children) and placebo
(39 children). Oxygen was used by 20 participants in the azithro-
mycin group (mean duration: 3.8 days +/- 0.4 standard error (SE))
and 31 participants in the placebo group (mean duration 3.4 days
+/- 0.3). Other outcomes are tabled and discussed in later sections
of this review as appropriate (Table 1).
McCallum 2013 randomised 97 children aged 18 months or un-
der, admitted with a clinical diagnosis of bronchiolitis (according
to standardised hospital protocols; months or under, with cough
and coryza, wheezing with or without crackles, respiratory dis-
tress with both tachypnoea (respiratory rate > 50 breaths/minute)
and retractions) to receive either a single large dose (30 mg/kg)
of azithromycin (50 children) or placebo (47 children) within 24
hours of hospitalisation. One of the primary outcomes was length
of oxygen requirement. The mean difference (MD) in oxygen re-
quirementwas not statistically significant between groups; azithro-
mycin 1.9 days versus placebo 2.7 days (MD -0.74; 95% confi-
dence interval (CI) -1.88 to 0.39).
Pinto 2012 randomised children less than 12 months of age, hos-
pitalised with acute viral bronchiolitis, to receive either azithromy-
cin (88 children) or placebo (96 children) for seven days. One of
the primary outcomes was duration of oxygen requirement. There
was no statistically significant difference in duration of oxygen
requirement in this study; azithromycin 4.4 days versus placebo
4.89 days (MD -0.49; 95% CI -1.35 to 0.37).
For duration of supplementary oxygen use we combined three
studies comparing azithromycin versus placebo in a meta-analysis
(Kneyber 2008; McCallum 2013; Pinto 2012). The three studies
providing adequate data for days of supplementary oxygen showed
no difference between antibiotics and placebo (pooled MD -0.20;
95% CI -0.72 to 0.33) (Analysis 1.1). Acceptable statistical het-
erogeneity was demonstrated for these results (Chi² test = 3.11, df
= 2 (P value = 0.21); I² statistic = 36%).
2. Oxygen saturation
Mazumder 2009 randomised infants younger than 24 months
(and older than one month) with clinically suspected bronchiolitis
to intravenous ampicillin (29 children), oral erythromycin (32
children) and no antibiotics (43 children). Symptoms (wheeze,
shortness of breath, oxygen saturation less than 96%, lack of social
smile and feeding difficulties) were measured on days one, three
and five. No significant differences were reported between the
three groups for oxygen saturation less than 96%. Full results as
reported by this study for the three groups are tabled with Chi
2 test results and significance levels (Table 2). The two antibiotic
arms of this trial were also combined and compared with control.
Again there was no significant difference between antibiotics and
control for the outcome of oxygen saturation less than 96%.
3. Wheeze
Mazumder 2009 found there were significantly fewer children
with wheeze in the oral erythromycin group on day three but
significantly fewer children with wheeze in the control group on
day five.When the two antibiotic arms of this trial were combined
and compared with control, for the outcome of wheeze on day
three, significantly fewer children had wheeze in the antibiotics
arm (odds ratio (OR) 0.27; 95% CI 0.12 to 0.62). However, on
day five significantly more children in the antibiotics arm had
wheeze compared with control (OR 5.55; 95% CI 1.18 to 26.05)
(Analysis 2.1).
4. Crepitations
None of the included studies explored this outcome.
5. Fever
Kabir 2009 randomised infants younger than24monthswith clin-
ical signs of bronchiolitis (hospitalised with runny nose, cough,
breathing difficulty, chest indrawing and rhonchi on auscultation).
Symptom resolution was measured as rapid (less than four days)
or gradual (more than four days). None of the symptom measures
(including fever on day two) differed significantly between par-
enteral ampicillin, oral erythromycin and control (Table 3).
There was no significant difference found in duration of fever
(days) in Kneyber 2008 when comparing azithromycin versus
placebo (Table 1).
While Kabir 2009 and Mazumder 2009 have the same interven-
tion arms, results could not be combined in ameta-analysis as they
either measured symptoms at markedly different times (for exam-
ple, fever, wheeze, cough, shortness of breath) or used an incompa-
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rable measure (for example, oxygen saturation < 96% (Mazumder
2009) versus oxygen saturation < 90% (Kabir 2009)).
Secondary outcomes
1. Duration of admission/time to discharge from hospital
In Tahan 2007, median hospital stay on clarithromycin was 2.13
days (interquartile range: 2 to 2.83) compared to 3.67 days (3
to 4.17) for placebo. In Kneyber 2008, the outcome of length of
hospital admission was 5.5 days (standard deviation (SD) 2.55)
in the azithromycin group and 5.82 days (SD 2.0) in the placebo
group, resulting in aMDof -0.32 (95%CI -1.40 to 0.76). In Pinto
2012, the use of azythromycin did not reduce the mean number
of days of hospitalisation; azithromycin 5.18 versus placebo 5.81
(MD -0.63; 95% CI -1.52 to 0.26).
McCallum 2013 demonstrated no statistically significant differ-
ence in mean length of stay; azithromycin 2.7 days versus placebo
3.6 days (MD -0.90; 95% CI -2.12 to 0.32). In Kabir 2009,
length of hospital stay did not differ significantly between par-
enteral ampicillin and oral erythromycin and control.
For length of hospital stay, we combined data from three studies
comparing the use of azithromycin versus placebo (Kneyber 2008;
McCallum 2013; Pinto 2012). We excluded one study from this
meta-analysis because of poor methodological quality and clini-
cal heterogeneity in that it compared erythromycin with placebo
(Kabir 2009). The three studies providing adequate data for length
of hospital admission similarly showed no difference between an-
tibiotics (azithromycin) and placebo (pooled MD -0.58; 95% CI
-1.18 to 0.02) (Analysis 4.1). Again, acceptable statistical hetero-
geneity was demonstrated for these results (Chi² test = 0.40, df =
2 (P value = 0.82); I² statistic = 0%).
2. Readmissions
In Tahan 2007, one participant was readmitted in the clar-
ithromycin group (8.3%) and four in the placebo group (44%).
McCallum 2013 explored hospital respiratory readmissions six
months post discharge as a primary outcome. The number of chil-
dren readmitted was similar, with 10 per group (OR 0.93; 95%
CI 0.35 to 2.47). These two studies providing sufficient data to
compare hospital readmissions found no significant difference but
we did not pool data owing to a substantial risk of heterogeneity
(I2 statistic = 59%) (McCallum 2013; Tahan 2007).
3. Complications/adverse events developed, including death
There were no deaths reported in any arms of any of the seven
included trials.
4. Radiological findings
Radiological findings were not reported as an outcome in any of
the included studies.
D I S C U S S I O N
Summary of main results
Six included studies did not find any difference between antibiotics
and placebo for their primary outcomes of length of illness (Field
1966) or length of hospital stay (Kabir 2009; Kneyber 2008;
Mazumder 2009; McCallum 2013; Pinto 2012). One small study
with a high risk of bias found that three weeks of clarithromycin
significantly reduced hospital admission compared to placebo (
Tahan 2007). This reduction in hospital readmissions was not
replicated in a more recent study that randomised 97 children to
receive either a single large dose of azithromycin or placebo (n
= 50 azithromycin, n = 47 placebo) (McCallum 2013). Another
study with a high risk of bias found mixed results for the effects
of antibiotics on wheeze but no difference for other symptom
measures (Mazumder 2009).
We only combined data for deaths, duration of supplementary
oxygen use and length of hospital stay. There were no deaths in
any arms of any of the seven included trials. For duration of sup-
plementary oxygen use, we combined three studies comparing
azithromycin versus placebo (Kneyber 2008; McCallum 2013;
Pinto 2012). The three studies providing adequate data for days
of supplementary oxygen showed no difference between antibi-
otics and placebo (pooled mean difference (MD) -0.20; 95% con-
fidence interval (CI) -0.72 to 0.33). For length of hospital stay, we
combined data from three studies comparing the use of azithromy-
cin versus placebo as a subtotal as part of the overall analysis of the
effect of antibiotics on hospital stay (Kneyber 2008; McCallum
2013; Pinto 2012).One other study comparing erythromycinwith
placebo was not included because its addition resulted in statisti-
cally significant heterogeneity of the pooled results. This study had
a higher risk of bias and it used a different antibiotic (erythromycin
rather than azithromycin) as the intervention (Kabir 2009). The
three studies providing adequate data for length of hospital admis-
sion similarly showed no difference between antibiotics (azithro-
mycin) and placebo, providing a pooled MD of -0.58 days (95%
CI -1.18 to 0.02) with acceptable statistical heterogeneity. Two
studies providing sufficient data to compare hospital readmissions
showed no significant difference between antibiotic and placebo
groups but we did not pool data as there was a substantial risk of
heterogeneity (I2statistic = 59%) (McCallum 2013; Tahan 2007).
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Overall completeness and applicability of
evidence
Clinicians may be concerned that if they do not use antibiotics in
a child presenting with a fever and clinical symptoms and signs
of bronchiolitis, they may be putting the child at risk of serious
complications such as pneumonia, septicaemia and death. It has
already been noted that children with this presentation are very
unlikely to have an occult bacteraemia (Greenes 1999). In one
study, paediatricians were less likely to evaluate febrile infants pre-
senting with clinical signs of bronchiolitis for sepsis. In this series
of 219 febrile infants with clinical signs of bronchiolitis, none had
a serious bacterial infection and it was concluded that selective
evaluation for sepsis in this population of febrile infants is appro-
priate (Luginbuhl 2008).
In addition to the four new randomised controlled trials (RCTs)
included in the 2011 update, this 2014 updated review includes
a further two new RCTs, all of which investigated the use of
macrolide antibiotics for bronchiolitis. Macrolides are thought
to have anti-inflammatory activities as well as antibiotic activ-
ity (Culic 2001), and so were thought to have potential in treat-
ing bronchiolitis, a viral condition. Additionally, clarithromycin, a
macrolide antibiotic, has been shown to have immune modulatory
effects (Ichiyama 2001). One included study hypothesised that
clarithromycin would be beneficial for bronchiolitis and found
clinical benefit from clarithromycin (Tahan 2007). However, firm
conclusions about the benefits of clarithromycin for bronchiolitis
cannot be drawn from this study of 21 participants because of the
small numbers and the high risk of potential bias.
Another study examining a macrolide antibiotic, azithromycin,
hypothesised that macrolide antibiotics would make no differ-
ence in bronchiolitis and this was what this study found (Kneyber
2008). Kneyber 2008 was a larger study and had fewer quality ap-
praisal concerns. The twonew included studies in this 2014update
also demonstrated no statistically significant benefit of azithromy-
cin compared to placebo for their primary outcomes (McCallum
2013; Pinto 2012). The pooled result of these three studies for
length of hospital admission was close to attaining statistical sig-
nificance. However, the pooled result shows a potential reduction
of only half a day in hospital, which represents approximately a
10% decrease in hospital time, which is of dubious clinical signif-
icance for an outcome which depends on many structural factors
independent of the disease course. Azithromycin also has a long
half-life, which may contribute to increased risk of emerging re-
sistant strains of bacteria.
Mazumder 2009 and Kabir 2009 compared intravenous ampi-
cillin and oral erythromycin for bronchiolitis and found no sig-
nificant difference between the two. There was also no significant
difference with control. For Mazumder 2009, the mixed results of
antibiotics on the outcome of wheeze and high risk of potential
bias mean that this study cannot support the use of antibiotics
in bronchiolitis. No firm conclusions can be drawn from the em-
pirical evidence contained in this review regarding the benefits of
macrolide antibiotics for bronchiolitis.
None of the studies specifically reported on adverse effects of an-
tibiotics. Only two studies made general comments that no ad-
verse effectswere foundwith antibiotic use (Field 1966;McCallum
2013).
Methods to reduce antibiotic use for bronchiolitis have been in-
vestigated. Wilson 2002 found that a clinical pathway reduced
inpatient antibiotic use for bronchiolitis from 27% to 9%.
Children with a serious illness requiring admission to intensive
care, and especially those requiring ventilation, may have higher
rates of bacterial co-infection, possibly justifying the increased use
of antibiotics in this setting (Kneyber 2005; Thorburn 2006).
There have been noRCTs assessing the usefulness of antibiotics for
bronchiolitis in an intensive care setting. Bloomfield 2004 found
that aside from intensive care admission (2.9% with bacteraemia),
childrenwith a respiratory syncytial virus (RSV) infection aremore
likely to be bacteraemic if they have a nosocomial RSV infection
(6.5% bacteraemia) or cyanotic congenital heart disease (6.6%
bacteraemia). The baseline rate of bacteraemia in children with
RSV bronchiolitis in this study was 0.6%. However, a small study
conducted in a paediatric intensive care unit in the United States
found that otherwise low-risk infants (23 infants) with RSV bron-
chiolitis and respiratory failure had rates of concomitant bacterial
pneumonia at 20% or higher (Levin 2010). Further evaluation
of the risk of secondary bacterial infection following bronchiolitis
would help inform the role of antibiotics in this viral infection,
especially in the context of respiratory failure.
Quality of the evidence
This 2014 update saw the addition of two larger studies exam-
ining azithromycin versus placebo for bronchiolitis (McCallum
2013; Pinto 2012). These two studies combined involved a further
138 participants in the antibiotic arm and 143 participants in the
placebo arm and demonstrated no statistically significant benefit
of azithromycin compared to placebo for their primary outcomes.
Prior to this only three small RCTs had examined antibiotics ver-
sus placebo, with only 72 participants in the antibiotic arms and
72 participants in the placebo arms. The two previous studies de-
scribing adequate randomisation conducted in high-income coun-
tries did not find any difference between antibiotic and placebo
arms (Field 1966; Kneyber 2008). The study which found clar-
ithromycin more likely to reduce hospital admission than placebo
did not adequately describe randomisation nor allocation con-
cealment and 30% of those randomised were excluded owing to
co-administration of corticosteroids (Tahan 2007). The inconsis-
tency of results seems most likely to be owing to the differences
in methodological quality. The study by Tahan 2007 was the only
one to use clarithromycin and the only study to use antibiotics
for three weeks. Two studies have been conducted in low-income
countries (Kabir 2009;Mazumder 2009), with a further two being
conducted in upper-middle income countries (Pinto 2012; Tahan
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2007). Both Mazumder 2009 and Kabir 2009 were studies which
had a high risk of bias.
Potential biases in the review process
This 2014 updated review is stronger, owing to the inclusion of
a further two new RCTs and makes a substantial contribution,
especially with regards to the role of macrolides in bronchiolitis.
No new unpublished data have been included. However, the re-
view authors have no reason to suspect that the search strategy has
biased the review results. Raw data could not be obtained from
one study conducted 40 years ago (Field 1966), nor from Tahan
2007, Mazumder 2009 or Kabir 2009, which is a weakness of this
review. Some trial authors did provide raw data for this review
(Kneyber 2008; McCallum 2013; Pinto 2012).
Agreements and disagreements with other
studies or reviews
Excluded studies comparing antibiotics to placebo in participants
with bronchiolitis did not find any significant difference (Friis
1984).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Overall, this review does not support the use of antibiotics for
bronchiolitis. Antibiotics may be justified in children with bron-
chiolitis who have respiratory failure.
Implications for research
Research to identify a possible small subgroup of patients present-
ing with bronchiolitis-like symptoms who may benefit from an-
tibiotics is justified. These might include those with respiratory
failure, in intensive care, with nosocomially acquired respiratory
syncytial virus (RSV) and with cyanotic congenital heart disease.
Future research may include subgroups based on tests for specific
pathogens. Otherwise, research may be better focused on deter-
mining the reasons that clinicians use antibiotics so readily for
bronchiolitis and how to reduce use of antibiotics for bronchi-
olitis, as well as ways to reduce clinician anxiety about not using
antibiotics.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Field 1966
Methods Randomised controlled trial
Participants Babies
Interventions Ampicillin
Placebo
Outcomes Length of hospital stay
Symptoms (not specified)
Switch to treatment arm
Death
Notes No deaths or apparent side effects reported from the use of ampicillin
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised
Allocation concealment (selection bias) Unclear risk Risk unclear
Blinding (performance bias and detection
bias)
All outcomes
Low risk Patients were blinded but not doctors nor outcome as-
sessors
Incomplete outcome data (attrition bias)
All outcomes
High risk No intention-to-treat analysis but withdrawal rates were
acceptable
Selective reporting (reporting bias) Low risk
Other bias Unclear risk Funding sources donot appear to be identified. Beechams
Research Laboratories supplied both the ampicillin and
the placebo
Kabir 2009
Methods Randomised controlled trial
Participants Children under 2 years of age with clinical suspected bronchiolitis
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Kabir 2009 (Continued)
Interventions IV ampicillin (parenteral ampicillin 50 mg/kg/6-hourly + supportive care), oral ery-
thromycin (oral erythromycin 10 mg/kg 6-hourly + supportive care), control
Outcomes Respiratory rate, oxygen saturation, wheeze, fever, length of hospital stay, shortness of
breath
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
High risk Seems unlikely, not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk 32 participants dropped out (10%), 17 were referred to
paediatric intensive care and 15 withdrew from the study
or left the recruiting hospitals
Selective reporting (reporting bias) High risk
Other bias Low risk Bangladesh Medical Research Council funded this
project (through a grant from the World Bank)
Kneyber 2008
Methods Double-blinded, placebo-controlled, randomised controlled trial
Participants Hospitalised infants younger than 24 months with clinically confirmed viral lower res-
piratory tract infection
Interventions Azithromycin 10 mg/kg/day, once daily for 3 days
Outcomes Respiratory rate, accessory muscle use, malaise severity, disease complications, use of
alternative therapies, length of hospital stay, length of intensive care stay, deaths, need
for NG feeding
Notes -
Risk of bias
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Kneyber 2008 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Adequate block randomisation
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and doctors
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow-up
Selective reporting (reporting bias) Low risk
Other bias Unclear risk Funding sources do not appear to be iden-
tified
Mazumder 2009
Methods Randomised controlled trial
Participants Children aged 1 month to 2 years presenting to an outpatients department in a teaching
hospital
Interventions Supportive management, supportive management plus IV ampicillin, supportive man-
agement plus oral erythromycin
Outcomes Breathing difficulty, feeding difficulty, social smile, tachypnoea (rapid breathing), hy-
poxia, wheeze, rhonchi, crepitation, WBC, Hb, ESR, CRP, X-ray, rate of recovery
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Odds and evens
Allocation concealment (selection bias) Unclear risk Not discussed
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not specified
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Mazumder 2009 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not specified
Selective reporting (reporting bias) Unclear risk Unsure
Other bias Unclear risk Funding sources do not appear to be identified
McCallum 2013
Methods Randomised controlled trial
Participants Children aged≤ 18months, admittedwith a clinical diagnosis of bronchiolitis (according
to standardised hospital protocols; ≤ 18 months, with cough and coryza, wheezing
+/- crackles, respiratory distress with both tachypnoea (respiratory rate > 50 breaths/
minute) and retractions). The major reason why 450 children did not meet the inclusion
criteria was because they did not require supplemental oxygen or were admitted over the
weekend. During recruitment, 21 children admitted into intensive care were excluded
Interventions A single large dose (30 mg/kg) of azithromycin within 24 hours of hospitalisation
Outcomes Primary outcomes: length of stay for respiratory illness - time from admission to time
for ’ready for discharge’ (SpO2 consistently > 94% in air for > 16 hours and feeding
adequately), duration of O2 requirement
Other outcomes: any respiratory-related readmissions within 6 months of discharge and
identification of respiratory viruses and bacterial pathogens
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was stratified by age (≤ 6 or > 6months),
ethnicity (Indigenous or non-Indigenous) and site (Dar-
win or Townsville). Randomisation was by computer-
generated permuted blocks
Allocation concealment (selection bias) Low risk Treatment allocation was concealed by opaque stickers.
Upon enrolment, children were assigned the next treat-
ment on the appropriate stratified list
Blinding (performance bias and detection
bias)
All outcomes
Low risk Neither the study team (researchers, hospital staff ) nor
parents were aware of the assigned treatment group until
the end of the trial. The placebo medication was man-
ufactured by the Institute of Drug Technology Australia
Limited (Melbourne, Victoria). It had a similar smell and
taste to active azithromycin. Azithromycin (Pfizer, Aus-
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McCallum 2013 (Continued)
tralia) was repackaged by IDT. Both medications were
prepared as powder in identical opaque bottled and sealed
with an aluminium foil
Incomplete outcome data (attrition bias)
All outcomes
Low risk 97 childrenwere recruited anddata from96 childrenwere
analysed. One participant was excluded from the analysis
of primary outcomes; they had received amacrolide in the
previous 7 days (this child was randomised to placebo)
. This child was included in the analysis of secondary
outcomes
Selective reporting (reporting bias) Low risk
Other bias Low risk Study was funded by grants from the Channel 7 Founda-
tion (seed funding 2007), the Financial Markets Foun-
dation for Children (for 2 years), and supported by a Na-
tional Health andMedical Research Council (NHMRC)
Centre for Research Excellence in Lung Health of Abo-
riginal and Torres Strait Islander Children (grant number
1040830). GBM is supported by a NHMRC scholarship
(grant 1055262), AC is funded by a NHMRC practi-
tioner fellowship (grant 545216). The funders had no
role in study design, data collection and analysis, decision
to publish, or preparation of the manuscript
Pinto 2012
Methods Randomised controlled trial
Participants Children < 12 months of age hospitalised with acute viral bronchiolitis
Interventions Azithromycin administered orally for 7 days
Outcomes Length of hospitalisation and duration of oxygen requirement
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Infants were randomised (simple/unrestricted randomi-
sation) to receive either a daily oral dose of azithromycin
or an equivalent volume of placebo
Allocation concealment (selection bias) Unclear risk Not described
19Antibiotics for bronchiolitis in children under two years of age (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Pinto 2012 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The patients were infants. A blinded study team mem-
ber supervised the intervention. A standardised form was
used to collect clinical information on the patients in-
cluded in the trial. Whether or not the outcome assessors
were blind to the intervention was not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Of 185 patients, 1 patient was lost to follow-up in the
placebo group. Data from 184 patients were analysed
Selective reporting (reporting bias) Low risk
Other bias Low risk Funded by Fundacao de Amparo a Pesquisa do Estado
do Rio Grande do Sul, which did not participate in the
collection, analysis or interpretation of data, nor in the
writing or the decision to submit the manuscript
Tahan 2007
Methods Double-blind, randomised controlled trial
Participants Infants less than or equal to 7 months with immunologically confirmed RSV infection
admitted to 1 hospital
Interventions Clarithromycin 15 mg/kg/day, once daily for 3 weeks
Outcomes Respiratory rate, wheeze, use of supplemental oxygen, cyanosis, hospital admission,
length of stay
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “... infants were randomised by a single
study nurse...”
“Simple randomisation was used”
Allocation concealment (selection bias) Unclear risk Allocation after enrolment by study nurse
Blinding (performance bias and detection
bias)
All outcomes
Low risk Blinding of patients and investigators
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 30 patients were randomised, however 9
were later excluded as they received corti-
costeroid therapy
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Tahan 2007 (Continued)
Selective reporting (reporting bias) Unclear risk Unsure if trial was registered
Other bias Unclear risk Unsure if there were any conflicts of inter-
est; funding sources do not appear to be
identified
CRP: C-reactive protein
ESR: erythrocyte sedimentation rate
Hb: haemoglobin
IV: intravenous
NG: nasogastric
RSV: respiratory syncytial virus
WBC: white blood count
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Boogaard 2007 Did not study antibiotics
Friis 1984 The patient selection criteria were fine crepitations or consolidation on chest radiograph, which was not consistent
with our inclusion criteria of a purely clinical presentation of bronchiolitis
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D A T A A N D A N A L Y S E S
Comparison 1. Use of alternative therapy (including duration of supplementary oxygen requirement)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Days of supplementary oxygen 3 350 Mean Difference (IV, Fixed, 95% CI) -0.20 [-0.72, 0.33]
2 Use of alternative therapy 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Oxygen 1 71 Odds Ratio (M-H, Fixed, 95% CI) 0.43 [0.15, 1.24]
2.2 Bronchodilator use 1 71 Odds Ratio (M-H, Fixed, 95% CI) 0.79 [0.31, 2.02]
2.3 Corticosteroid use 1 71 Odds Ratio (M-H, Fixed, 95% CI) 0.15 [0.02, 1.27]
2.4 Nasogastric feeding 1 71 Odds Ratio (M-H, Fixed, 95% CI) 1.44 [0.56, 3.69]
3 Duration of bronchodilator use 1 71 Mean Difference (IV, Fixed, 95% CI) -0.20 [-1.28, 0.88]
4 Days of tube feeding 1 71 Mean Difference (IV, Fixed, 95% CI) 0.10 [-0.95, 1.15]
Comparison 2. Symptoms
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Wheeze 2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Day 1 1 104 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Day 3 1 104 Odds Ratio (M-H, Fixed, 95% CI) 0.27 [0.12, 0.62]
1.3 Day 5 1 104 Odds Ratio (M-H, Fixed, 95% CI) 5.55 [1.18, 26.05]
1.4 Day 7 1 295 Odds Ratio (M-H, Fixed, 95% CI) 2.18 [0.71, 6.68]
2 Shortness of breath 2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Day 1 1 104 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Day 3 1 104 Odds Ratio (M-H, Fixed, 95% CI) 0.75 [0.34, 1.66]
2.3 Day 5 1 104 Odds Ratio (M-H, Fixed, 95% CI) 0.66 [0.28, 1.55]
2.4 Day 7 1 295 Odds Ratio (M-H, Fixed, 95% CI) 4.46 [1.01, 19.72]
3 Oxygen saturation (< 96%) 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Day 1 1 104 Odds Ratio (M-H, Fixed, 95% CI) 1.02 [0.47, 2.24]
3.2 Day 3 1 104 Odds Ratio (M-H, Fixed, 95% CI) 2.48 [0.83, 7.44]
3.3 Day 5 1 104 Odds Ratio (M-H, Fixed, 95% CI) 1.83 [0.34, 9.91]
4 Not smiling socially 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Day 1 1 104 Odds Ratio (M-H, Fixed, 95% CI) 0.83 [0.36, 1.91]
4.2 Day 3 1 104 Odds Ratio (M-H, Fixed, 95% CI) 0.83 [0.24, 2.91]
4.3 Day 5 1 104 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Feeding difficulties 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Day 1 1 104 Odds Ratio (M-H, Fixed, 95% CI) 0.5 [0.23, 1.10]
5.2 Day 3 1 104 Odds Ratio (M-H, Fixed, 95% CI) 0.83 [0.24, 2.91]
5.3 Day 5 1 104 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Fever 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
6.1 Day 2 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Cough 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 Day 7 1 295 Odds Ratio (M-H, Fixed, 95% CI) 3.33 [0.96, 11.53]
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Comparison 3. Duration of symptoms
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Duration of symptoms 2 123 Mean Difference (IV, Fixed, 95% CI) 0.32 [-1.14, 1.78]
2 Duration of fever [days] 1 71 Mean Difference (IV, Fixed, 95% CI) 0.5 [-0.09, 1.09]
Comparison 4. Hospital admissions/time to discharge from hospital
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Length of hospital stay 4 Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Azithromycin versus
placebo
3 350 Mean Difference (IV, Random, 95% CI) -0.58 [-1.18, 0.02]
1.2 Erythromycin versus
placebo
1 196 Mean Difference (IV, Random, 95% CI) 0.70 [0.22, 1.18]
Comparison 5. Readmissions
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Readmission 2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
Comparison 6. PICU admission
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 PICU admission 1 71 Odds Ratio (M-H, Fixed, 95% CI) 0.39 [0.02, 10.03]
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Comparison 7. Death
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Deaths 5 543 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Analysis 1.1. Comparison 1 Use of alternative therapy (including duration of supplementary oxygen
requirement), Outcome 1 Days of supplementary oxygen.
Review: Antibiotics for bronchiolitis in children under two years of age
Comparison: 1 Use of alternative therapy (including duration of supplementary oxygen requirement)
Outcome: 1 Days of supplementary oxygen
Study or subgroup Antibiotics Placebo/control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[days] N Mean(SD)[days] IV,Fixed,95% CI IV,Fixed,95% CI
McCallum 2013 50 1.9 (1.22) 46 2.7 (3.74) 21.6 % -0.80 [ -1.93, 0.33 ]
Pinto 2012 88 4.4 (2.54) 95 4.9 (3.38) 37.3 % -0.50 [ -1.36, 0.36 ]
Kneyber 2008 32 3.8 (1.74) 39 3.4 (1.78) 41.1 % 0.40 [ -0.42, 1.22 ]
Total (95% CI) 170 180 100.0 % -0.20 [ -0.72, 0.33 ]
Heterogeneity: Chi2 = 3.59, df = 2 (P = 0.17); I2 =44%
Test for overall effect: Z = 0.73 (P = 0.47)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Antibiotics Placebo/control
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Analysis 1.2. Comparison 1 Use of alternative therapy (including duration of supplementary oxygen
requirement), Outcome 2 Use of alternative therapy.
Review: Antibiotics for bronchiolitis in children under two years of age
Comparison: 1 Use of alternative therapy (including duration of supplementary oxygen requirement)
Outcome: 2 Use of alternative therapy
Study or subgroup Antibiotics Placebo/control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Oxygen
Kneyber 2008 20/32 31/39 100.0 % 0.43 [ 0.15, 1.24 ]
Subtotal (95% CI) 32 39 100.0 % 0.43 [ 0.15, 1.24 ]
Total events: 20 (Antibiotics), 31 (Placebo/control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.57 (P = 0.12)
2 Bronchodilator use
Kneyber 2008 17/32 23/39 100.0 % 0.79 [ 0.31, 2.02 ]
Subtotal (95% CI) 32 39 100.0 % 0.79 [ 0.31, 2.02 ]
Total events: 17 (Antibiotics), 23 (Placebo/control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
3 Corticosteroid use
Kneyber 2008 1/32 7/39 100.0 % 0.15 [ 0.02, 1.27 ]
Subtotal (95% CI) 32 39 100.0 % 0.15 [ 0.02, 1.27 ]
Total events: 1 (Antibiotics), 7 (Placebo/control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.74 (P = 0.081)
4 Nasogastric feeding
Kneyber 2008 16/32 16/39 100.0 % 1.44 [ 0.56, 3.69 ]
Subtotal (95% CI) 32 39 100.0 % 1.44 [ 0.56, 3.69 ]
Total events: 16 (Antibiotics), 16 (Placebo/control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.45)
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Analysis 1.3. Comparison 1 Use of alternative therapy (including duration of supplementary oxygen
requirement), Outcome 3 Duration of bronchodilator use.
Review: Antibiotics for bronchiolitis in children under two years of age
Comparison: 1 Use of alternative therapy (including duration of supplementary oxygen requirement)
Outcome: 3 Duration of bronchodilator use
Study or subgroup Antibiotics Placebo/control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[days] N Mean(SD)[days] IV,Fixed,95% CI IV,Fixed,95% CI
Kneyber 2008 32 2.8 (2.49) 39 3 (2.06) 100.0 % -0.20 [ -1.28, 0.88 ]
Total (95% CI) 32 39 100.0 % -0.20 [ -1.28, 0.88 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
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Analysis 1.4. Comparison 1 Use of alternative therapy (including duration of supplementary oxygen
requirement), Outcome 4 Days of tube feeding.
Review: Antibiotics for bronchiolitis in children under two years of age
Comparison: 1 Use of alternative therapy (including duration of supplementary oxygen requirement)
Outcome: 4 Days of tube feeding
Study or subgroup Antibiotics Placebo/control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[days] N Mean(SD)[days] IV,Fixed,95% CI IV,Fixed,95% CI
Kneyber 2008 32 1.9 (2.13) 39 1.8 (2.36) 100.0 % 0.10 [ -0.95, 1.15 ]
Total (95% CI) 32 39 100.0 % 0.10 [ -0.95, 1.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Antibiotics Placebo/control
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Analysis 2.1. Comparison 2 Symptoms, Outcome 1 Wheeze.
Review: Antibiotics for bronchiolitis in children under two years of age
Comparison: 2 Symptoms
Outcome: 1 Wheeze
Study or subgroup Antibiotics Placebo/control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Day 1
Mazumder 2009 61/61 43/43 Not estimable
Subtotal (95% CI) 61 43 Not estimable
Total events: 61 (Antibiotics), 43 (Placebo/control)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Day 3
Mazumder 2009 18/61 26/43 100.0 % 0.27 [ 0.12, 0.62 ]
Subtotal (95% CI) 61 43 100.0 % 0.27 [ 0.12, 0.62 ]
Total events: 18 (Antibiotics), 26 (Placebo/control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.09 (P = 0.0020)
3 Day 5
Mazumder 2009 13/61 2/43 100.0 % 5.55 [ 1.18, 26.05 ]
Subtotal (95% CI) 61 43 100.0 % 5.55 [ 1.18, 26.05 ]
Total events: 13 (Antibiotics), 2 (Placebo/control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.17 (P = 0.030)
4 Day 7
Kabir 2009 17/198 4/97 100.0 % 2.18 [ 0.71, 6.68 ]
Subtotal (95% CI) 198 97 100.0 % 2.18 [ 0.71, 6.68 ]
Total events: 17 (Antibiotics), 4 (Placebo/control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
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Analysis 2.2. Comparison 2 Symptoms, Outcome 2 Shortness of breath.
Review: Antibiotics for bronchiolitis in children under two years of age
Comparison: 2 Symptoms
Outcome: 2 Shortness of breath
Study or subgroup Antibiotics Placebo/control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Day 1
Mazumder 2009 61/61 43/43 Not estimable
Subtotal (95% CI) 61 43 Not estimable
Total events: 61 (Antibiotics), 43 (Placebo/control)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Day 3
Mazumder 2009 34/61 27/43 100.0 % 0.75 [ 0.34, 1.66 ]
Subtotal (95% CI) 61 43 100.0 % 0.75 [ 0.34, 1.66 ]
Total events: 34 (Antibiotics), 27 (Placebo/control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
3 Day 5
Mazumder 2009 16/61 15/43 100.0 % 0.66 [ 0.28, 1.55 ]
Subtotal (95% CI) 61 43 100.0 % 0.66 [ 0.28, 1.55 ]
Total events: 16 (Antibiotics), 15 (Placebo/control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
4 Day 7
Kabir 2009 17/198 2/97 100.0 % 4.46 [ 1.01, 19.72 ]
Subtotal (95% CI) 198 97 100.0 % 4.46 [ 1.01, 19.72 ]
Total events: 17 (Antibiotics), 2 (Placebo/control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.97 (P = 0.049)
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Analysis 2.3. Comparison 2 Symptoms, Outcome 3 Oxygen saturation (< 96%).
Review: Antibiotics for bronchiolitis in children under two years of age
Comparison: 2 Symptoms
Outcome: 3 Oxygen saturation (< 96%)
Study or subgroup Antibiotics Placebo/control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Day 1
Mazumder 2009 33/61 23/43 100.0 % 1.02 [ 0.47, 2.24 ]
Subtotal (95% CI) 61 43 100.0 % 1.02 [ 0.47, 2.24 ]
Total events: 33 (Antibiotics), 23 (Placebo/control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
2 Day 3
Mazumder 2009 15/61 5/43 100.0 % 2.48 [ 0.83, 7.44 ]
Subtotal (95% CI) 61 43 100.0 % 2.48 [ 0.83, 7.44 ]
Total events: 15 (Antibiotics), 5 (Placebo/control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.62 (P = 0.11)
3 Day 5
Mazumder 2009 5/61 2/43 100.0 % 1.83 [ 0.34, 9.91 ]
Subtotal (95% CI) 61 43 100.0 % 1.83 [ 0.34, 9.91 ]
Total events: 5 (Antibiotics), 2 (Placebo/control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
Test for subgroup differences: Chi2 = 1.74, df = 2 (P = 0.42), I2 =0.0%
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Analysis 2.4. Comparison 2 Symptoms, Outcome 4 Not smiling socially.
Review: Antibiotics for bronchiolitis in children under two years of age
Comparison: 2 Symptoms
Outcome: 4 Not smiling socially
Study or subgroup Antibiotics Placebo/control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Day 1
Mazumder 2009 40/61 30/43 100.0 % 0.83 [ 0.36, 1.91 ]
Subtotal (95% CI) 61 43 100.0 % 0.83 [ 0.36, 1.91 ]
Total events: 40 (Antibiotics), 30 (Placebo/control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
2 Day 3
Mazumder 2009 6/61 5/43 100.0 % 0.83 [ 0.24, 2.91 ]
Subtotal (95% CI) 61 43 100.0 % 0.83 [ 0.24, 2.91 ]
Total events: 6 (Antibiotics), 5 (Placebo/control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
3 Day 5
Mazumder 2009 0/61 0/43 Not estimable
Subtotal (95% CI) 61 43 Not estimable
Total events: 0 (Antibiotics), 0 (Placebo/control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 1.00), I2 =0.0%
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Analysis 2.5. Comparison 2 Symptoms, Outcome 5 Feeding difficulties.
Review: Antibiotics for bronchiolitis in children under two years of age
Comparison: 2 Symptoms
Outcome: 5 Feeding difficulties
Study or subgroup Antibiotics Placebo/control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Day 1
Mazumder 2009 25/61 25/43 100.0 % 0.50 [ 0.23, 1.10 ]
Subtotal (95% CI) 61 43 100.0 % 0.50 [ 0.23, 1.10 ]
Total events: 25 (Antibiotics), 25 (Placebo/control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.72 (P = 0.086)
2 Day 3
Mazumder 2009 6/61 5/43 100.0 % 0.83 [ 0.24, 2.91 ]
Subtotal (95% CI) 61 43 100.0 % 0.83 [ 0.24, 2.91 ]
Total events: 6 (Antibiotics), 5 (Placebo/control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
3 Day 5
Mazumder 2009 0/61 0/43 Not estimable
Subtotal (95% CI) 61 43 Not estimable
Total events: 0 (Antibiotics), 0 (Placebo/control)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 2.6. Comparison 2 Symptoms, Outcome 6 Fever.
Review: Antibiotics for bronchiolitis in children under two years of age
Comparison: 2 Symptoms
Outcome: 6 Fever
Study or subgroup Antibiotics Placebo/control Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Day 2
Kabir 2009 11/198 4/97 1.37 [ 0.42, 4.41 ]
0.01 0.1 1 10 100
Antibiotics Placebo/control
Analysis 2.7. Comparison 2 Symptoms, Outcome 7 Cough.
Review: Antibiotics for bronchiolitis in children under two years of age
Comparison: 2 Symptoms
Outcome: 7 Cough
Study or subgroup Antibiotics Placebo/control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Day 7
Kabir 2009 19/198 3/97 100.0 % 3.33 [ 0.96, 11.53 ]
Subtotal (95% CI) 198 97 100.0 % 3.33 [ 0.96, 11.53 ]
Total events: 19 (Antibiotics), 3 (Placebo/control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.89 (P = 0.058)
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Analysis 3.1. Comparison 3 Duration of symptoms, Outcome 1 Duration of symptoms.
Review: Antibiotics for bronchiolitis in children under two years of age
Comparison: 3 Duration of symptoms
Outcome: 1 Duration of symptoms
Study or subgroup Antibiotics Placebo/control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[days] N Mean(SD)[days] IV,Fixed,95% CI IV,Fixed,95% CI
Field 1966 28 9.54 (0) 24 9.7 (0) Not estimable
Kneyber 2008 32 4.94 (3.78) 39 4.62 (2.05) 100.0 % 0.32 [ -1.14, 1.78 ]
Total (95% CI) 60 63 100.0 % 0.32 [ -1.14, 1.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Duration of symptoms, Outcome 2 Duration of fever [days].
Review: Antibiotics for bronchiolitis in children under two years of age
Comparison: 3 Duration of symptoms
Outcome: 2 Duration of fever [days]
Study or subgroup Antibiotics Placebo/control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Kneyber 2008 32 1.5 (1.41) 39 1 (1.08) 100.0 % 0.50 [ -0.09, 1.09 ]
Total (95% CI) 32 39 100.0 % 0.50 [ -0.09, 1.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.65 (P = 0.099)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Hospital admissions/time to discharge from hospital, Outcome 1 Length of
hospital stay.
Review: Antibiotics for bronchiolitis in children under two years of age
Comparison: 4 Hospital admissions/time to discharge from hospital
Outcome: 1 Length of hospital stay
Study or subgroup Antibiotics Placebo/control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[days] N Mean(SD)[days] IV,Random,95% CI IV,Random,95% CI
1 Azithromycin versus placebo
Kneyber 2008 32 5.5 (2.55) 39 5.8 (2) 30.6 % -0.30 [ -1.38, 0.78 ]
McCallum 2013 50 2.7 (1.42) 46 3.6 (4) 24.1 % -0.90 [ -2.12, 0.32 ]
Pinto 2012 88 5.2 (2.89) 95 5.8 (3.26) 45.3 % -0.60 [ -1.49, 0.29 ]
Subtotal (95% CI) 170 180 100.0 % -0.58 [ -1.18, 0.02 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.52, df = 2 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 1.90 (P = 0.058)
2 Erythromycin versus placebo
Kabir 2009 99 4.4 (1.93) 97 3.7 (1.45) 100.0 % 0.70 [ 0.22, 1.18 ]
Subtotal (95% CI) 99 97 100.0 % 0.70 [ 0.22, 1.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.87 (P = 0.0040)
Test for subgroup differences: Chi2 = 10.72, df = 1 (P = 0.00), I2 =91%
-10 -5 0 5 10
Antibiotics Placebo/control
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Analysis 5.1. Comparison 5 Readmissions, Outcome 1 Readmission.
Review: Antibiotics for bronchiolitis in children under two years of age
Comparison: 5 Readmissions
Outcome: 1 Readmission
Study or subgroup Antibiotics Placebo/control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
McCallum 2013 10/50 10/47 0.93 [ 0.35, 2.47 ]
Tahan 2007 1/12 4/9 0.11 [ 0.01, 1.29 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 11 (Antibiotics), 14 (Placebo/control)
Heterogeneity: Chi2 = 0.0, df = 0 (P<0.00001); I2 =0.0%
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Antibiotics Placebo/control
Analysis 6.1. Comparison 6 PICU admission, Outcome 1 PICU admission.
Review: Antibiotics for bronchiolitis in children under two years of age
Comparison: 6 PICU admission
Outcome: 1 PICU admission
Study or subgroup Antibiotics Placebo/control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kneyber 2008 0/32 1/39 100.0 % 0.39 [ 0.02, 10.03 ]
Total (95% CI) 32 39 100.0 % 0.39 [ 0.02, 10.03 ]
Total events: 0 (Antibiotics), 1 (Placebo/control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.57)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Antibiotics Placebo/control
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Analysis 7.1. Comparison 7 Death, Outcome 1 Deaths.
Review: Antibiotics for bronchiolitis in children under two years of age
Comparison: 7 Death
Outcome: 1 Deaths
Study or subgroup Antibiotics Placebo/control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Field 1966 0/28 0/24 Not estimable
Kabir 2009 0/198 0/97 Not estimable
Kneyber 2008 0/32 0/39 Not estimable
Mazumder 2009 0/61 0/43 Not estimable
Tahan 2007 0/12 0/9 Not estimable
Total (95% CI) 331 212 Not estimable
Total events: 0 (Antibiotics), 0 (Placebo/control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Antibiotics Placebo/control
A D D I T I O N A L T A B L E S
Table 1. Kneyber: azithromycin versus placebo for bronchiolitis
Variable Azithromycin (n = 32) Placebo
(n = 39)
Outcome Significance level
Days of symptoms 4.94 (SD 3.78) 4.62 (SD 2.05) Mean difference 0.32 (95%
CI -1.14 to 1.78)
P value = 0.65
Days in hospital 5.5 (SD 2.54) 5.82 (SD 1.98) Mean difference -0.32
(95% CI -1.40 to 0.76)
P value = 0.56
Duration of fever (days) 1.47 (SD 1.41) 1.00 (SD 1.08) Mean difference 0.47 (95%
CI -0.12 to 1.06)
P value = 0.12
Duration of
bronchodilator use
2.79 (SD 2.49) 2.96 (SD 2.06) Mean difference -0.17
(95% CI -1.25 to 0.91)
P value = 0.81
Bronchodilator use 17 23 Odds ratio 0.79 (95% CI 0.
31 to 2.02)
P value = 0.62
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Table 1. Kneyber: azithromycin versus placebo for bronchiolitis (Continued)
Supplementary oxygen 20 (62.5%) 31 (79.49%) Odds ratio 0.43 (95% CI 0.
15 to 1.24)
P value = 0.11
Days of extra oxygen 3.75 (SD 1.74) 3.39 (SD 1.78) Mean difference 0.36 (95%
CI -0.46 to 1.18)
P value = 0.48
PICU admission 0 (0%) 1 (2.56%) Odds ratio 0.39 (95% CI 0.
02 to 10.03)
P value = 1.00
Tube feeding 16 (50.00%) 16 (41.03%) Odds ratio 1.44 (95% CI 0.
56 to 3.69)
P value = 0.45
Days of tube feeding 1.90 (SD 2.13) 1.83 (SD 2.36) Mean difference 0.07 (95%
CI -0.98 to 1.12)
P value = 0.90
CI: confidence interval
PICU: paediatric intensive care unit
SD: standard deviation
Table 2. Mazumder: IV ampicillin versus oral erythromycin versus control
Vari-
able
Day 1 Out-
come
Day 3 Out-
come
Day 5 Out-
come
IV
ampi-
cillin
Oral
ery-
thromycin
Control Chi
2 test (P
value)
IV
ampi-
cillin
Oral
ery-
thromycin
Control Chi
2 test (P
value)
IV
ampi-
cillin
Oral
ery-
thromycin
Control Chi2
test
(P
value)
Wheeze 29/29
(100%)
32/32
(100%)
43/43
(100%)
N/A 16/29
(55%)
2/32
(6%)
26/43
(60%)
24.82
(P value
< 0.
001)
6/29
(21%)
7/32
(22%)
2/43
(5%)
5.69 (P
value =
0.058)
Short-
ness of
breath
29/29
(100%)
32/32
(100%)
43/43
(100%)
N/A 18/29
(62%)
16/32
(50%)
27/43
(63%)
1.97 (P
value =
0.37)
8/29
(28%)
8/32
(25%)
15/43
(35%)
0.95 (P
value =
0.62)
Oxygen
satura-
tion (<
96%)
18/29
(62%)
15/32
(47%)
23/43
(53%)
1.42 (P
value =
0.49)
8/29
(28%)
7/32
(22%)
5/43
(12%)
3.05 (P
value =
0.22)
2/29
(7%)
3/32
(9%)
2/43
(5%)
0.65 (P
value =
0.72)
Not
smiling
socially
19/29
(66%)
21/32
(66%)
30/43
(70%)
0.20 (P
value =
0.90)
3/29
(10%)
3/32
(9%)
5/43
(12%)
0.10 (P
value =
0.95)
0/29
(0%)
0/32
(0%)
0/43
(0%)
N/A
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Table 2. Mazumder: IV ampicillin versus oral erythromycin versus control (Continued)
Feed-
ing dif-
ficulty
12/29
(41%)
13/32
(41%)
25/43
(58%)
2.98 (P
value =
0.23)
3/29
(10%)
3/32
(9%)
5/43
(12%)
0.10 (P
value =
0.95)
0/29
(0%)
0/32
(0%)
0/43
(0%)
N/A
IV: intravenous
Table 3. Kabir: IV ampicillin versus oral erythromycin versus control
Variable Intervention Outcome
IV ampicillin Oral erythromycin Control Chi2 test (P value)
Day 2
Oxygen sats (< 90%) 2/99 (2%) 6/99 (6%) 6/97 (6%) 2.45 (P value = 0.29)
Fever 5/99 (5%) 6/99 (6%) 4/97 (4%) 0.38 (P value = 0.83)
Day 7
Wheeze 8/99 (8%) 9/99 (9%) 4/97 (4%) 2.04 (P value = 0.36)
Shortness of breath 8/99 (8%) 9/99 (9%) 2/97 (2%) 4.68 (P value = 0.10)
Cough 10/99 (10%) 9/99 (9%) 3/97 (3%) 4.06 (P value = 0.13)
CI: confidence interval
IV: intravenous
PICU: paediatric intensive care unit
SD: standard deviation
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A P P E N D I C E S
Appendix 1. MEDLINE (Ovid) search strategy
1 exp Bronchiolitis/
2 bronchiolit$.mp.
3 exp Respiratory Syncytial Viruses/
4 exp Respiratory Syncytial Virus Infections/
5 (respiratory syncytial virus$ or RSV$).mp.
6 1 or 2 or 3 or 4 or 5
7 exp Anti-Bacterial Agents/
8 antibiotic$.mp.
9 exp Macrolides/
10 (macrolide$ or azithromycin or clarithromycin or erythromycin or roxithromycin or spiramycin).mp.
11 exp Cephalosporins/
12 (cephalosporin$ or cephalexin or cephaclor or cefaclor or cefepime or cefotaxime or cephamycin$ or cefotetan or cefoxitin or
cefmetazole or cefpirome or cefpodoxime or ceftazidime or ceftriaxone or cephamandole or cephazolin).mp.
13 exp Penicillins/
14 (penicillin$ or amoxicillin or amoxycillin or ampicillin or benzylpenicillin or cloxacillin or dicloxacillin or flucloxacillin or piperacillin
or ticarcillin or sulbactam).mp.
15 exp Fluoroquinolones/
16 (fluoroquinolone$ or ciprofloxacin or enoxacin or norfloxacin or ofloxacin or pefloxacin or fleroxacin or levofloxacin or moxi-
floxacin).mp.
17 exp Tetracycline/
18 (tetracycline$ or doxycycline or methacycline or minocycline).mp.
19 (amikacin or gentamicin or neomycin or netilmicin).mp.
20 (clindamycin or lincomycin).mp.
21 (chloramphenicol or amantadine or cotrimoxazole or trimethoprim).mp.
22 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21
23 exp Child/
24 (children or infant$ or pediatric or pediatric).mp.
25 23 or 24
26 6 and 22 and 25
Appendix 2. Embase.com search strategy
#36 #24 AND #35
#35 #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #33 OR #34
#34 #31 AND #32
#33 placebo*
#32 blind* OR mask*
#31 single* OR doubl* OR trebl* OR tripl*
#30 clinical AND trial*
#29 ’double blind’ OR ’single blind’
#28 ’placebo’/exp
#27 ’clinical trial’/exp
#26 random*
#25 ’randomized controlled trial’/exp
#24 #23 AND [embase]/lim
#23 #19 AND #22
#22 #20 OR #21
#21 child* OR infant* OR pediatric* OR pediatric*
#20 ’child’/exp
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#19 #5 AND #18
#18 #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17
#17 tetracycline* OR doxycycline OR methacycline OR minocycline OR amikacin OR gentamicin OR neomycin OR netilmicin OR
clindamycin OR lincomycin OR chloramphenicol OR amantadine OR cotrimoxazole OR trimethoprim
#16 ’tetracycline derivative’/exp
#15 fluoroquinolone* OR ciprofloxacin OR enoxacin OR norfloxacin OR ofloxacin OR pefloxacin OR fleroxacin OR levofloxacin
OR moxifloxacin
#14 ’quinolone derivative’/exp
#13 penicillin* OR amoxicillin OR amoxycillin OR ampicillin OR benzylpenicillin OR cloxacillin OR dicloxacillin OR flucloxacillin
OR piperacillin OR ticarcillin OR sulbactam
#12 ’penicillin derivative’/exp
#11 cephalosporin* OR cephalexin OR cephaclor OR cefaclor OR cefepime OR cefotaxime OR cephamycin* OR cefotetan OR
cefoxitin OR cefmetazole OR cefpirome OR cefpodoxime OR ceftazidime OR ceftriaxone OR cephamandole OR cephazolin
#10 ’cephalosporin derivative’/exp
#9 macrolide* OR azithromycin OR clarithromycin OR erythromycin OR roxithromycin OR spiramycin
#8 ’macrolide’/exp
#7 antibiotic*
#6 ’antibiotic agent’/exp
#5 #1 OR #2 OR #3 OR #4
#4 ’respiratory syncytial virus’ OR ’respiratory syncytial viruses’ OR ’respiratory syncytial virus infection’ OR ’respiratory syncytial virus
infections’ OR rsv*
#3 ’respiratory syncytial pneumovirus’/exp
#2 bronchiolit*
#1 ’bronchiolitis’/exp
Appendix 3. Current Contents search strategy
# 11 #10 AND #9 AND #8 Databases=ABES, SBS, CM, LS, PCES, ECT, AH, EC, BC
# 10 #7 OR #6 OR #5 OR #4 OR #3 Databases=ABES, SBS, CM, LS, PCES, ECT, AH, EC, BC
# 9 #2 OR #1 Databases=ABES, SBS, CM, LS, PCES, ECT, AH, EC, BC
# 8 Topic=(Child* or infant* or pediatric or paediatric) Databases=ABES, SBS, CM, LS, PCES, ECT, AH, EC, BC
# 7 Topic=(tetracycline* or doxycycline or methacycline or minocycline or amikacin or gentamicin or neomycin or netilmicin or
clindamycin or lincomycin or chloramphenicol or amantadine or cotrimoxazole or trimethoprim) Databases=ABES, SBS, CM, LS,
PCES, ECT, AH, EC, BC
# 6 Topic=(fluoroquinolone* or ciprofloxacin or enoxacin or norfloxacin or ofloxacin or pefloxacin or fleroxacin or levofloxacin or
moxifloxacin) Databases=ABES, SBS, CM, LS, PCES, ECT, AH, EC, BC
# 5 Topic=(penicillin* or amoxicillin or amoxycillin or ampicillin or benzylpenicillin or cloxacillin or dicloxacillin or flucloxacillin or
piperacillin or ticarcillin or sulbactam)Databases=ABES, SBS, CM, LS, PCES, ECT, AH, EC, BC
# 4 Topic=(cephalosporin* or cephalexin or cephaclor or cefaclor or cefepime or cefotaxime or cephamycin* or cefotetan or cefoxitin or
cefmetazole or cefpirome or cefpodoxime or ceftazidime or ceftriaxone or cephamandole or cephazolin) Databases=ABES, SBS, CM,
LS, PCES, ECT, AH, EC, BC
# 3 Topic=(macrolide* or azithromycin or clarithromycin or erythromycin or roxithromycin or spiramycin) Databases=ABES, SBS,
CM, LS, PCES, ECT, AH, EC, BC
# 2 Topic=(Respiratory syncytial pneumovirus or Respiratory Syncytial Virus or Respiratory Syncytial Viruses or Respiratory Syncytial
Virus Infection or Respiratory Syncytial Virus Infections or RSV*) Databases=ABES, SBS, CM, LS, PCES, ECT, AH, EC, BC
# 1 Topic=(Bronchiolit*)Databases=ABES, SBS, CM, LS, PCES, ECT, AH, EC, BC
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WH A T ’ S N E W
Last assessed as up-to-date: 16 June 2014.
Date Event Description
16 June 2014 New search has been performed We updated the electronic searches and identified
two new randomised controlled trials for inclusion (
McCallum 2013; Pinto 2012), examining the role of
azithromycin versus placebo for bronchiolitis
16 June 2014 New citation required but conclusions have not changed Our conclusions remain unchanged.
H I S T O R Y
Protocol first published: Issue 2, 2005
Review first published: Issue 1, 2007
Date Event Description
10 December 2010 New citation required and conclusions have changed A new review author joined the team to update the
review. The conclusions are stronger as they are based
on more trials and address the question of macrolide
antibiotics for bronchiolitis
10 December 2010 New search has been performed We updated the searches and included four new trials
(Kabir 2009; Kneyber 2008; Mazumder 2009; Tahan
2007).
1 August 2008 Amended Converted to new review format.
C O N T R I B U T I O N S O F A U T H O R S
RF joined the review team for this 2014 update. RF reviewed search results, contacted authors, entered data and drafted the text for
this update.
GS co-wrote the protocol, reviewed search results, performed quality appraisal, extracted data, drafted the original text for this review
and assisted in writing the text for this update.
CDM gave advice on performing the systematic review, performed quality appraisal, extracted data and assisted in writing the text for
this update and previous versions of this review.
LE conducted the literature search and approved the final version.
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D E C L A R A T I O N S O F I N T E R E S T
Rebecca Farley: none known.
Geoffrey KP Spurling: none known.
Lars Eriksson: none known.
Chris B Del Mar: none known.
S O U R C E S O F S U P P O R T
Internal sources
• University of Queensland, Australia.
In kind
External sources
• No sources of support supplied
I N D E X T E R M S
Medical Subject Headings (MeSH)
Ampicillin [therapeutic use]; Anti-Bacterial Agents [∗therapeutic use]; Azithromycin [therapeutic use]; Bronchiolitis [∗drug therapy;
mortality]; Clarithromycin [therapeutic use]; Erythromycin [therapeutic use]; Length of Stay; Randomized Controlled Trials as Topic
MeSH check words
Humans; Infant
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